US Aid Freeze Disrupts Global Health Supply Chains; Mirum Pharma's Breakthrough, Eli Lilly Bets on Weight-Loss Drug

The US foreign aid freeze causes disruption in the supply chain for vital medical products in poorer countries, affecting diseases like HIV and malaria. Other health updates include FDA drug approvals, company financial maneuvers, and a rise in measles cases. Key developments impact the health sector globally.

A U.S. government freeze on foreign aid has critically disrupted supply chains for essential medical products aimed at fighting diseases such as HIV and malaria in some of the world's poorest nations. The impact, according to insiders, could result in months-long life-threatening gaps.

Meanwhile, the FDA has approved a genetic disorder drug by Mirum Pharmaceuticals, targeting a rare cholesterol processing issue. This approval marks a milestone in treating cerebrotendinous xanthomatosis.

In other news, Eli Lilly is taking a significant financial leap with a $550 million stockpile of an experimental weight-loss drug, anticipating its future approval and market entry. This proactive move underscores the company's commitment to addressing obesity with advanced solutions.